Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.42000.0000 (0.00%)
At close: 04:00PM EDT
2.3700 -0.05 (-2.07%)
After hours: 04:08PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Performance Outlook
Previous Close2.4200
Open2.4200
Bid2.2200 x 800
Ask2.4500 x 1800
Day's Range2.3800 - 2.4550
52 Week Range1.7950 - 4.5000
Volume422,222
Avg. Volume840,904
Market Cap317.775M
Beta (5Y Monthly)1.42
PE Ratio (TTM)30.25
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-9% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ORGO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organogenesis Holdings Inc.
    ORGO: What does Argus have to say about ORGO?ORGANOGENESIS HOLDINGS INC has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • GlobeNewswire

    Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

    CANTON, Mass. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from Septemb

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

    CANTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30th, 2023. Second Quarter 2023 Financial Results Summary: Net revenue of $117.3 million for the second quarter of 2023, a decrease of $4.1 million

  • GlobeNewswire

    Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

    CANTON, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, August 9th. Management will host a conference call at 5:00 p.m. Eastern Time on August

Advertisement
Advertisement